bevacizumab,atezolizumab
roche
['imbrave050', 'hcc']
 asco-hcc qol data from imbrave050 - no evident decrease in qol for patients treated with adjuvant a+b will it be enough to lead to the approval? #asco23 
Medical Oncologist and PhD student at Imperial College London.
HCC, immuno-oncology.
Curiosity-driven.